Positioning Vamorolone in Duchenne Care

This sponsored multi-part series examines the evolving role of vamorolone in the care of patients with Duchenne muscular dystrophy (DMD). Through conversations with clinical experts across specialties, the series explores the clinical data, safety considerations, and real-world positioning of vamorolone within modern DMD treatment strategies. Each episode offers focused insight into how this therapy may influence both short- and long-term care decisions.

In Part 2 of this series, the conversation turns to how vamorolone is being integrated into everyday neuromuscular practice. Led by Migvis Monduy, MD, pediatric neurologist and medical director of the Cerebral Palsy and Neuromotor Center at Nicklaus Children’s Hospital, this episode focuses on how clinicians approach steroid selection in young patients with Duchenne muscular dystrophy.

In this initial episode, Monduy discusses how vamorolone’s efficacy and differentiated safety profile factor into treatment planning, particularly in conversations around growth, bone health, behavioral effects, and long-term steroid exposure. The discussion highlights the importance of individualized care and how having an additional steroid option may shape shared decision-making with families navigating this complex disease.